KRAS and non-small cell lung carcinoma: The PGM3 competitive inhibitor known as FR054 attenuates EGFR-Akt signaling and triggers ER stress and ROS, leading to diminished tumor growth and increased cell death of KRAS/LKB-mutant NSCLC cells in vitro and in vivo.